Harrow Inc. (NASDAQ:HROW) posted mixed results for the fourth quarter on Tuesday.The eye disease medicine maker, Harrow, reported fourth quarter earnings of 17 cents per share, missing the consensus estimate of 38 cents. Sales jumped from $66.81 million to $89.09 million, beating the consensus of $88.45 million.During the fourth quarter and full-year ended December 31, 2025, Harrow recorded $8.5 million in acquired in-process research and development expenses related to its acquisition of Melt Pharmaceutica ...